Mondrian Investment Partners LTD decreased its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 35.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,738,748 shares of the company’s stock after selling 4,341,214 shares during the quarter. Mondrian Investment Partners LTD’s holdings in Takeda Pharmaceutical were worth $108,342,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of TAK. Capital Research Global Investors raised its position in shares of Takeda Pharmaceutical by 3.6% during the 4th quarter. Capital Research Global Investors now owns 14,297,805 shares of the company’s stock valued at $204,030,000 after buying an additional 503,446 shares in the last quarter. Van ECK Associates Corp increased its holdings in shares of Takeda Pharmaceutical by 21.1% in the second quarter. Van ECK Associates Corp now owns 2,040,829 shares of the company’s stock worth $26,408,000 after buying an additional 356,069 shares during the period. OLD Mission Capital LLC lifted its stake in shares of Takeda Pharmaceutical by 1,440.9% in the 4th quarter. OLD Mission Capital LLC now owns 1,041,526 shares of the company’s stock valued at $14,863,000 after acquiring an additional 973,935 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Takeda Pharmaceutical by 1.7% during the 4th quarter. Wells Fargo & Company MN now owns 774,552 shares of the company’s stock valued at $11,053,000 after acquiring an additional 12,756 shares during the period. Finally, Cowen AND Company LLC bought a new position in Takeda Pharmaceutical during the 2nd quarter worth approximately $6,866,000. 9.17% of the stock is owned by hedge funds and other institutional investors.
Takeda Pharmaceutical Price Performance
Shares of Takeda Pharmaceutical stock opened at $14.85 on Wednesday. The stock has a market capitalization of $47.25 billion, a P/E ratio of 27.00, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $16.39. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.26 and a quick ratio of 0.74. The business’s 50 day simple moving average is $14.23 and its two-hundred day simple moving average is $13.74.
Takeda Pharmaceutical Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Further Reading
- Five stocks we like better than Takeda Pharmaceutical
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Box Office Revival: 3 Movie Theater Stocks Making a Comeback
- What Are Dividend Champions? How to Invest in the Champions
- Brace for the Perfect Storm: Rate Cuts and a Slow September
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 3 Small-to-Mid-cap Stocks to Buy and Hold for 2025
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.